日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy

HLX10 识别 PD-1 受体的结构基础,一种有前景的抗 PD-1 抗体临床候选药物,可用于癌症免疫治疗

Hassan Issafras ,Shilong Fan ,Chi-Ling Tseng ,Yunchih Cheng ,Peihua Lin ,Lisa Xiao ,Yun-Ju Huang ,Chih-Hsiang Tu ,Ya-Chin Hsiao ,Min Li ,Yen-Hsiao Chen ,Chien-Hsin Ho ,Ou Li ,Yanling Wang ,Sandra Chen ,Zhenyu Ji ,Eric Zhang ,Yi-Ting Mao ,Eugene Liu ,Shumin Yang ,Weidong Jiang

Characterization of murine CEACAM1 in vivo reveals low expression on CD8+ T cells and no tumor growth modulating activity by anti-CEACAM1 mAb CC1

小鼠 CEACAM1 体内表征表明,抗 CEACAM1 mAb CC1 在 CD8+ T 细胞上表达较低,且不具有肿瘤生长调节活性

Robbie L McLeod, Minilik H Angagaw, Toya Nath Baral, Liming Liu, Raymond Joseph Moniz, Jason Laskey, SuChun Hsieh, Mike Lee, Jin-Hwan Han, Hassan Issafras, Sarah Javaid, Andrey Loboda, Svetlana Sadekova, Joann A O'Connor, Archie Tse, Juha Punnonen

Application of an In Vivo Hepatic Triacylglycerol Production Method in the Setting of a High-Fat Diet in Mice

体内肝三酰甘油生产方法在小鼠高脂饮食环境中的应用

Kikumi D Ono-Moore, Matthew Ferguson, Michael L Blackburn, Hassan Issafras, Sean H Adams

Inhibition of insulin receptor function by a human, allosteric monoclonal antibody: a potential new approach for the treatment of hyperinsulinemic hypoglycemia

人类变构单克隆抗体抑制胰岛素受体功能:治疗高胰岛素血症性低血糖症的潜在新方法

John A Corbin, Vinay Bhaskar, Ira D Goldfine, Hassan Issafras, Daniel H Bedinger, Angela Lau, Kristen Michelson, Lisa M Gross, Betty A Maddux, Hua F Kuan, Catarina Tran, Llewelyn Lao, Masahisa Handa, Susan R Watson, Ajay J Narasimha, Shirley Zhu, Raphael Levy, Lynn Webster, Sujeewa D Wijesuriya, Nai

Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1β antibody with differential receptor-modulating properties

具有不同受体调节特性的变构抗 IL-1β 抗体 gevokizumab 的详细机制分析

Hassan Issafras, John A Corbin, Ira D Goldfine, Marina K Roell

XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases

XOMA 052 是一种强效、高亲和力的单克隆抗体,用于治疗 IL-1β 介导的疾病

Alexander M Owyang, Hassan Issafras, John Corbin, Kiran Ahluwalia, Paul Larsen, Elizabeth Pongo, Masahisa Handa, Arnold H Horwitz, Marina K Roell, Mary Haak-Frendscho, Linda Masat

Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity

利用XOMA 052(一种调节白细胞介素-1β活性的治疗性抗体)进行通路衰减的动力学方法

Marina K Roell ,Hassan Issafras, Robert J Bauer, Kristen S Michelson, Nerissa Mendoza, Sandra I Vanegas, Lisa M Gross, Paul D Larsen, Daniel H Bedinger, David J Bohmann, Genevieve H Nonet, Naichi Liu, Steve R Lee, Masahisa Handa, Seema S Kantak, Arnold H Horwitz, John J Hunter, Alexander M Owyang, Amer M Mirza, John A Corbin, Mark L White